卵巢上皮癌组织中hMSH2的表达及其与化疗耐药的关系

发布时间：2018-06-15 02:47

  本文选题：卵巢癌 + hMSH　； 参考：《肿瘤防治研究》2015年06期

【摘要】：目的检测不同化疗敏感程度的卵巢上皮癌组织中hMSH2基因的表达,分析其与化疗耐药及预后的关系。方法 80例新鲜卵巢上皮癌组织均由手术中取得,采用ATP-TCA技术检测卵巢癌组织对八种药物:紫杉醇、卡铂、拓泊替康、多西他赛、吉西他滨、环磷酰胺体内代谢产物、依托泊苷及博来霉素的体外敏感性。采用Real-time PCR及Westernblot法分别检测80例卵巢上皮癌组织中hMSH2基因mRNA和蛋白水平的表达情况。结果对紫杉醇耐药的卵巢上皮癌组中,hMSH2基因在mRNA及蛋白水平的表达均明显高于敏感组(P0.01),在对卡铂、拓泊替康、多西他赛耐药组中hMSH2表达水平也明显高于敏感组(P0.05);hMSH2基因的相对表达值与卡铂、拓泊替康、多西他赛的敏感度系数有显著相关性(P≤0.05)。早期卵巢癌患者组织的hMSH2表达水平明显低于晚期卵巢癌组织(P0.05)。高、中分化卵巢癌组织hMSH2蛋白表达水平明显低于低分化卵巢癌组织(P=0.000)。原发卵巢癌患者组织的hMSH2表达水平明显低于复发卵巢癌患者组织(P0.01)。结论 hMSH2基因的高表达与卵巢癌化疗耐药及预后相关,化疗可能诱导hMSH2基因的高表达;下调hMSH2基因的表达或许是逆转肿瘤耐药的新途径。
[Abstract]:Objective to detect the expression of hMSH2 gene in ovarian epithelial carcinoma with different chemosensitivity, and to analyze its relationship with chemotherapeutic resistance and prognosis. Methods Eighty cases of fresh ovarian epithelial carcinoma were obtained by operation. ATP-TCA technique was used to detect the metabolites of eight drugs in ovarian cancer tissues: paclitaxel, carboplatin, topotecan, docetaxel, gemcitabine, cyclophosphamide. In vitro sensitivity of etoposide and bleomycin. Real-time PCR and Western blot were used to detect the expression of hMSH2 mRNA and protein in 80 cases of ovarian epithelial carcinoma. Results the expression of hMSH2 gene in paclitaxel-resistant ovarian epithelial carcinoma was significantly higher than that in sensitive group (P 0.01), and in carboplatin and topotecan. The expression level of hMSH2 in docetaxel resistant group was significantly higher than that in sensitive group (P < 0.05). There was a significant correlation between the relative expression value of hMSH2 gene and the sensitivity coefficient of carboplatin, topotecan and docetaxel (P 鈮，

本文编号：2020240